KENGREXAL®

CANGRELOR (powder for concentrate for solution for injection/infusion)

#BIOSCIENCE

Kengrexal, co-administered with acetylsalicylic acid (ASA), is indicated for the reduction of thrombotic cardiovascular events in adult patients with coronary artery disease undergoing percutaneous coronary intervention (PCI), who have not received an oral P2Y12 receptor inhibitor prior to the procedure and for whom oral administration of such treatment is not feasible or desirable.

1
Summary of product characteristics
base-donnees-publique.medicaments.gouv.fr
2
​​Opinion of the Transparency Commission, High Authority of Health
has-sante.fr